Synonyms: ABT-414
Compound class:
Antibody
Comment: Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate (ADC), which targets a unique tumour-specific EGFR epitope in some cancer cells [5]. The antibody portion recognises EGFR in glioblastoma cells with EGFR gene amplification or expressing the truncated Δ2-7 EGFR mutant (aka EGFRvIII) [2-3]. The antibody is linked to the cytotoxic agent, monomethyl auristatin F (MMAF; PubChem CID 56841603) (information derived from Phillips et al. (2013) [4] and Abbvie's webpage for oncology pipeline compounds and references therein [1].
|
Classification | |
Compound class | Antibody |
International Nonproprietary Names | |
INN number | INN |
10263 | depatuxizumab mafodotin |
Synonyms |
ABT-414 |
Database Links | |
GtoPdb PubChem SID | 249565653 |
Search PubMed clinical trials | depatuxizumab mafodotin |
Search PubMed titles | depatuxizumab mafodotin |
Search PubMed titles/abstracts | depatuxizumab mafodotin |